The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | ZUMA-1, JULIET and TRANSCEND trials: changing the treatment landscape for R/R NHL
David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, provides an overview of key updates in treatment for relapsed/refractory non-Hodgkin lymphoma (NHL), specifically the ZUMA-1 (NCT02348216), JULIET (NCT02445248), and TRANSCEND (NCT02631044) trials investigating the use of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, respectively. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Dr Maloney discusses the safety and efficacy, including PFS and CR rates from these trials.
